British drug maker AstraZeneca Plc (AZN.L, AZN) and MSD Inc., known as Merck & Co., Inc. (MRK) inside the U.S. and Canada, on Tuesday announced positive results from the Phase III POLO trial, saying that the trial met its primary endpoint of progression-free survival or PFS.
Original Article: AstraZeneca, MSD Say Phase III POLO Trial Meets Primary Endpoint Of PFS